Loading people...
Igor DaCruz is the Managing Director and Head of Credit and Portfolio for the Life Sciences group at Trinity Capital, based in the San Francisco Bay Area. Prior to this role, he served as Managing Director of Life Sciences at Runway Growth Capital, pioneering the firm's first funding deal for a pre-FDA approved therapeutics company. He previously held the position of Managing Director and Head of Life Sciences at Union Bank, expanding his expertise in venture debt and corporate banking. Earlier in his career, DaCruz worked at Silicon Valley Bank, leading a team responsible for managing a diversified portfolio of over 300 technology and life sciences clients. With over 13 years of financial experience, his current focus centers on structuring growth debt investments and managing portfolio risk for early-stage biotechnology and enterprise software startups.
Igor DaCruz is a distinguished Managing Director at Runway Growth Capital, a leading provider of growth debt to venture and growth-backed companies. In his role, Igor is instrumental in the firm's core operations, encompassing the origination, underwriting, and meticulous portfolio management of growth debt investments. His contributions are vital to Runway Growth Capital's mission of empowering innovative companies with the capital they need to scale without significant equity dilution.
Runway Growth Capital's investment strategy centers on providing flexible, non-dilutive growth capital to high-growth companies, primarily within the technology and life sciences sectors. Igor's expertise aligns perfectly with this focus, as he actively seeks out and evaluates promising businesses in areas such as enterprise software, fintech, healthcare IT, consumer internet, and various biotechnology and medical device sub-sectors. He works closely with founders and management teams to structure financing solutions that support product development, market expansion, and operational scaling, ensuring companies can achieve their strategic milestones.
Before joining Runway Growth Capital, Igor honed his skills and deep industry knowledge at Hercules Capital, another prominent growth debt provider, where he served as a Vice President. This experience equipped him with a comprehensive understanding of the unique financial needs and challenges faced by venture-backed companies. Prior to his tenure in growth debt, Igor began his career in investment banking as an Analyst at Morgan Stanley, focusing on Technology Mergers and Acquisitions. This foundational experience provided him with a strong analytical framework and a keen insight into the technology landscape, which he leverages daily in his current role. Igor is an alumnus of the Haas School of Business at the University of California, Berkeley, where he earned his B.S. in Business Administration.
While specific individual investments are often a collaborative effort within Runway Growth Capital, Igor has been a key contributor to the firm's impressive portfolio. Runway Growth Capital has a track record of backing transformative companies across various stages of growth. Igor's involvement ensures that the firm continues to identify and support the next generation of market leaders, helping them navigate complex growth phases with strategic capital. His commitment to fostering innovation and delivering tailored financial solutions makes him a valuable asset to both Runway Growth Capital and the companies it serves.
Igor DaCruz is a Managing Director at Runway Growth Capital, a firm specializing in growth debt for venture and growth-backed companies. He is responsible for originating, underwriting, and managing growth debt investments.
Igor DaCruz primarily invests in high-growth technology and life sciences companies. His focus areas include enterprise software, fintech, healthcare IT, consumer internet, biotechnology, and medical devices, providing non-dilutive growth capital.
Igor DaCruz works as a Managing Director at Runway Growth Capital, a leading provider of growth debt to innovative companies across the technology and life sciences sectors.
